[Inhibitory effect of antisense oligonucleotide of integrin-linked kinase on cell proliferation of human epithelial ovarian cancer].
OBJECTIVE
To explore the inhibitory effect of integrin-linked kinase antisense oligonucleotide (ILK-ASODN) on cell proliferation in human ovarian cancer cell line (HO8910).


METHODS
We transfected ILK-ASODN into HO8910 to block ILK gene expression, measured the expression levels of integrin-linked kinase (ILK) mRNA by RT-PCR and ILK protein by western-blotting; the inhibiting effects of the transfection on HO8910 proliferation, the cell cycles, and cell apoptosis were assessed by water soluble tetrazolium-1 (WST-1) and flow cytometry (FCM).


RESULTS
After transfection of ILK-ASODN, the expression levels of ILK mRNA decreased significantly in groups D, E, F being 0.307 +/- 0.011, 0.198 +/- 0.008, 0, respectively, when compared with those of the two control groups of A and B (P < 0.05). The expression levels of ILK protein of the groups D, E and F decreased significantly also, being 26.3 +/- 0.8, 20.6 +/- 0.4 and 0, respectively. HO8910 cell proliferation was inhibited significantly, and the rates of apoptosis of the groups D, E and F increased significantly, being 7.31%, 8.84% and 11.27% respectively. The cell population increased in G0/G1 phase of the groups D, E and F, being 49.25%, 56.28% and 67.61% respectively, significantly different in comparison with those of groups of A and B (P < 0.01).


CONCLUSIONS
Transfection of ILK-ASODN into human ovarian cancer line inhibited cancer cell proliferation significantly.
Li
Qi
Q
Department of Obstetrics and Gynecology, Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
Zhang
Yan-Hua
YH
Li
Pei-Ling
PL
Pei
Jun-Rui
JR
D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008081:Liposomes; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D000099200:Scaffold Protein ILK
D008081:Liposomes; D016376:Oligonucleotides, Antisense; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger; D000099200:Scaffold Protein ILK